Fabrício A Moreira1, José Alexandre S Crippa. 1. Department of Pharmacology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
Abstract
OBJECTIVE: Experimental evidence has suggested that drugs that enhance cannabinoid type-1 (CB1) receptor activity may induce anxiolytic and antidepressant effects, whilst the opposite has been reported with antagonists. Thus, the objective of the present review is to discuss the potential psychiatric side-effects of CB1 receptor antagonists, such as rimonabant, which has been recently marketed in several countries for the treatment of smoking cessation, obesity and associated metabolic disorders. METHOD: Literature searches were performed in PubMed and SciELO databases up to February 2009. The terms searched were 'obesity', 'rimonabant', 'cannabinoids', 'unwanted effects', 'diabetes', 'smoking cessation' and 'side-effects'. RESULTS: Clinical trials have revealed that rimonabant may promote weight loss in obese patients, although it may also induce symptoms of anxiety and depression. DISCUSSION: Patients taking CB1 receptor antagonists should be carefully investigated for psychiatric side-effects. These drugs should not be prescribed for those already suffering from mental disorders. Nevertheless, the development of new compounds targeting the endocannabinoid system for the treatment of several conditions would be necessary and opportune.
OBJECTIVE: Experimental evidence has suggested that drugs that enhance cannabinoid type-1 (CB1) receptor activity may induce anxiolytic and antidepressant effects, whilst the opposite has been reported with antagonists. Thus, the objective of the present review is to discuss the potential psychiatric side-effects of CB1 receptor antagonists, such as rimonabant, which has been recently marketed in several countries for the treatment of smoking cessation, obesity and associated metabolic disorders. METHOD: Literature searches were performed in PubMed and SciELO databases up to February 2009. The terms searched were 'obesity', 'rimonabant', 'cannabinoids', 'unwanted effects', 'diabetes', 'smoking cessation' and 'side-effects'. RESULTS: Clinical trials have revealed that rimonabant may promote weight loss in obesepatients, although it may also induce symptoms of anxiety and depression. DISCUSSION: Patients taking CB1 receptor antagonists should be carefully investigated for psychiatric side-effects. These drugs should not be prescribed for those already suffering from mental disorders. Nevertheless, the development of new compounds targeting the endocannabinoid system for the treatment of several conditions would be necessary and opportune.
Authors: Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis Journal: Psychopharmacology (Berl) Date: 2017-02-01 Impact factor: 4.530
Authors: Luigi Bellocchio; Edgar Soria-Gómez; Carmelo Quarta; Mathilde Metna-Laurent; Pierre Cardinal; Elke Binder; Astrid Cannich; Anna Delamarre; Martin Häring; Mar Martín-Fontecha; David Vega; Thierry Leste-Lasserre; Dusan Bartsch; Krisztina Monory; Beat Lutz; Francis Chaouloff; Uberto Pagotto; Manuel Guzman; Daniela Cota; Giovanni Marsicano Journal: Proc Natl Acad Sci U S A Date: 2013-03-04 Impact factor: 11.205
Authors: Miranda L Groft; Marigny C Normann; Paige R Nicklas; Julia E Jagielo-Miller; Peter J McLaughlin Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2019-07-09 Impact factor: 3.000
Authors: Laura Colino; Javier Herranz-Herrer; Elena Gil-Benito; Teresa Ponte-Lopez; Pablo Del Sol-Calderon; Maria Rodrigo-Yanguas; María Gil-Ligero; Antonio J Sánchez-López; Jose de Leon; Hilario Blasco-Fontecilla Journal: Curr Psychiatry Rep Date: 2018-03-15 Impact factor: 5.285
Authors: Mateus M Bergamaschi; Regina H C Queiroz; Marcos H N Chagas; Ila M P Linares; Kátia C Arrais; Danielle C G de Oliveira; Maria E Queiroz; Antonio E Nardi; Marilyn A Huestis; Jaime E C Hallak; Antonio W Zuardi; Fabrício A Moreira; José A S Crippa Journal: Hum Psychopharmacol Date: 2013-12-03 Impact factor: 1.672